← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV23행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyPreclinical
Advanced therapy (Advanced therapy)
Bristol-Myers Squibb·Ulcerative Colitis
ORR 22.7%
Overview
Program
Advanced therapy
Overview
Company
Bristol-Myers Squibb
Overview
Modality
ANTIBODY
Overview
Target
Ulcerative Colitis
Overview
Indication
Ulcerative Colitis
Overview
Phase
PRECLINICAL
Overview
Status
RECRUITING
MoA
Mechanism
checkpoint inhibitor-induced colitis
MoA
Biomarker
HER2-positive
PK/PD
Species
Rat
PK/PD
Animal (cat.)
Rat, In vitro
PK/PD
Experiment
PD
Toxicology
Species
Rat
Toxicology
Animal (cat.)
Rat, In vitro
Toxicology
Major finding
Comparison of Tacrolimus and Infliximab for Acute Severe Ulcerative Colitis in Hospitalized Adults: A Retrospective Study.. Comparative data on infliximab (IFX) and tacrolimus as salvage therapies for intravenous glucocorticoid (ivGC)-refractory acute severe ulcerative colitis (ASUC) are limited. We aimed to evaluate the effectiveness and safety of IFX versus tacrolimus in hospitalized patients wi…
Clinical
Primary efficacy
ORR 22.7%
Clinical
ORR
22.7%
Clinical
PFS
2.69
Clinical
OS
15.9
Clinical
Result source
ClinicalTrials.gov NCT02951767
Clinical
Data Tier / Score
A · 39
Clinical
Program phase
PRECLINICAL
Clinical
Clinical sync
2026년 7월 13일 (1일 전)